The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 2, 2003, Pages 115-120

  Matsagas, Miltiadis ^a   Jagroop, I Anita ^c   Geroulakos, George ^a   Mikhailidis, Dimitri P ^b  

^a EALING HOSPITAL   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Clopidogrel; Loading dose; Peripheral arterial disease; Platelet aggregation; Platelet shape change

Indexed keywords

ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PURINE P2 RECEPTOR; SEROTONIN;

ADULT; AGED; ARTERY DISEASE; ARTICLE; CLINICAL ARTICLE; FEMALE; FLUSHING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE SHAPE;

EID: 0038387201     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900204     Document Type: Article

References (47)

1. CAPRIE steering committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329.
2. Bertrand ME, Rupprecht HJ, Urban P, et al. for the CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624.
3. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34:1891.
4. Calver AL, Blows LJ, Harmer S, et al. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents. Am Heart J 2000;140:483.
5. Moussa I, Oetgen M, Roubin G, et al. Effectivness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99:2364.
6. Yusuf S, Zhao F, Metha SR, et al. The Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494.
7. Muller C, Buttner HJ, Petersen J, et al. A randomised comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101:590.
8. Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 2000;84:891.
9. Mikhailidis DP, Jagroop IA. Is clopidogrel markedly superior to aspirin in patients with peripheral vascular disease? Platelets 1998;9:273.
10. Wilde JI, Retzer M, Siess S, et al. ADP-induced platelet shape change: An investigation of the signaling pathways involved and their dependence on the methods of platelet preparation. Platelets 2000;11:286.
11. Geiger J, Birch J, Honig-Liedl P. Specific impairment of human platelet P2YAC ADP receptor-mediated signiling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999;19:2007.
12. Daniel JL, Dangelmaier C, Jin J, et al. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998;273:2024.
13. Gachet C. Identification, characterization, and inhibition of platelet ADP receptors. Int J Haematol 2001;74:375.
14. Kunapuli SP. Functional characterisation of platelet ADP receptors. Platelets 1998;9:343.
15. Puri RN, Colman RW. ADP-induced platelet activation. Crit Rev Biochem Mol Biol 1997;32:437.
16. Matsagas MI, Geroulakos G, Mikhailidis DP. The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 2002;16:246.
17. Hiatt WR. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy. J Intern Med 2002;251:193.
18. Robless P, Mikhailidis DP, Stansby. Systemic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. Br J Surg 2001;88:787.
19. Montalescott G. Value of antiplatelet therapy in preventing thrombotic events in generalised vascular disease. Clin Cardiol 2000;23:18.
20. Reininger CB, Boeger CA, Steckmeier B, et al. Mechanisms underlying increased platelet reactivity in patients with peripheral arterial disease. Preliminary results. Int Angiol 1999;18:163.
21. Barradas MA, Stansby G, Hamilton G, et al. Diminished platelet yield and enhanced platelet aggregability in platelet-rich plasma of peripheral vascular disease patients. Int Angiol 1994;13:202.
22. Saniabadi AR, Lowe GD, Baebenel JC, et al. The effect of dipyridamole on spontaneous platelet aggregation in whole blood decreases with the time after venepuncture: Evidence for the role of ADP. Thromb Haemost 1987;58:744.
23. Frojmovic MM, Milton JC, Duchastel A. Microscopic measurements of platelet aggregation reveal a low ADP-dependent process distinct from turbidometrically measured aggregation. J Lab Clin Med 1983;101:964.
24. Jagroop IA, Barradas MA, Mikhailidis DP. A low molecular weight heparin, nadroparin (Fraxiparine), inhibits thrombin induced platelet shape change and does not enhance spontaneous platelet aggregation. Br J Clin Pharmacol 1996;41:163.
25. Barradas MA, Jagroop A, O'Donoghue S, et al. Effect of milrinone in human platelet shape change, aggregation and thromboxane A2 synthesis: An in vitro study. Thromb Res 1993;71:227.
26. Barradas MA, Stansby G, Hamilton G, et al. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease. In Vivo 1993;7:543.
27. Whitworth NH, Barradas MA, Mikhailidis DP, et al. An investigation into the effects of bacterial lipopolysaccharide on human platelets. Eur J Haematol 1989;43:112.
28. Mikhailidis DP, Barradas MA, Epemolu O, et al. Ethanol ingestion inhibits human whole blood platelet impedance aggregation. Am J Clin Pathol 1987;88:342.
29. Jagroop IA, Geroulakos G, Matsagas M, et al. The effect of clopidogrel (Plavix) function in patients with peripheral vascular disease - comparison with aspirin. 1st International symposium on cardiovascular science from bench to bedside, Hong Kong. J Cardiac Surg 2002; in press.
30. 12, play a role in controlling shape change in humans platelets. Platelets 2002; in press.
31. Jagroop IA, Mikhailidis DP. Doxazosin, an alpha1-adrenoceptor antagonist, inhibits serotonin-induced shape change in human platelets. J Human Hypertens 2001;15:203.
32. Jagroop IA, Mikhailidis DP. Angiotensin II can induce and potentiate shape change in human platelets: Effect of losartan. J Human Hypertens 2000;14:581.
33. Jagroop IA, Clatworthy I, Lewin J, et al. Shape change in human platelets: Measurement with a channelyzer and visualisation by electron microscopy. Platelets 2000;11:28.
34. Jagroop IA, Mikhailidis DP. An investigation of the serotonergic effects of fenfluramine, dexfenfluramine and dexnorfenfluramine using platelets as neuronal models. Platelets 2000;11:156.
35. Jagroop IA, Mikhailidis DP. Effect of endothelin-1 on human platelet shape change: Reversal of activation by naftidrofuryl. Platelets 2000;11:272.
36. Barradas MA, O'Donoghue S, Mikhailidis DP. Measurement of platelet volume using a channelyzer: Assessment of the effect of agonists and antagonists. In vivo 1992;6:629.
37. Jagroop IA, Tsiara S, Mikhailidis DP. Mean platelet volume as an indicator of platelet activation: Methodological issues. Platelets 2002; in press.
38. Barradas MA, Gill DS, Fonseca VA, et al. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest 1988;4:399.
39. Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimes: Kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost 1999;25:15.
40. Qawi I, Robson SC. New developments in antiplatelet therapies: Potential use of CD39/vascular ATP diphosphohydrolase in thrombotic disorders. Curr Drug Targets 2000;1:285.
41. Umemura K, Ishihara H, Nakashima M. Anti-platelet effects of clopidogrel in rat middle cerebral artery thrombosis model. Thromb Res 1995;80:209.
42. Yao SK, McNatt J, Cui K, et al. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in non-human primates. Circulation 1993;88:2888.
43. Hirata Y, Umemura K, Uematsu T, et al. An experimental myocardial infarction model in the rat and its properties. Jap J Pharmacol 1995;67:51.
44. Dale J, Myhre E, Rootwelt K. Effects of dipyridamole and acetylsalicylic acid on platelet functions in patients with aortic ball-valve prostheses. Am Heart J 1975;89:613.
45. Fuster V, Chesebro JH, Frye RL, et al. Platelet survival and the development of coronary artery disease in the young adult: Effects of cigarette smoking, strong family history and medical therapy. Circulation 1981;63:546.
46. Maurer-Spurej E, Devine DV. Platelet aggregation is not initiated by platelet shape change. Lab Invest 2001;81:1517.
47. Cheshire HJ, Wolfe JH, Barradas MA, et al. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin markers for postoperative infrainguinal graft stenosis. Eur J Endovasc Surg 1996;4:479.